Phase 2b VISTAS Study to Treat PSC-Related Pruritus Completes Enrollment

On September 8, 2025, Mirum Pharmaceuticals Inc. issued a press release announcing enrollment completion for the Phase 2b VISTAS study. This clinical trial is studying volixibat versus placebo to treat pruritus (itch) associated with PSC. Volixibat works by reducing bile acids in the blood, which may decrease the frequency and severity of pruritus.

The VISTAS study targeted an enrollment of 200 adult and pediatric (12 years and older) participants living with PSC. Earlier blinded interim results showed a sufficient improvement in pruritus and no safety concerns, allowing the study to continue and complete enrollment. An initial summary of final results of the trial are expected in the 2nd quarter of 2026.

There are currently no approved treatments for pruritus or other PSC related symptoms. If successful, this study may support the FDA approval of the first drug to treat this debilitating PSC symptom.

PSC Partners is deeply grateful for every person living with PSC who chooses to participate in clinical trials, including this study. Your participation enables development of safe and effective treatments for PSC for all. We will continue to update the community as more information becomes available regarding this study.

Read the full press release from Mirum on their website.